Skip to main content

Table 1 Baseline characteristics of clinical data of asthenozoospermia in each group

From: Studies on improving semen quality and increasing pregnancy chances through the in vitro addition of L-carnitine and coenzyme Q10 to semen in patients with asthenozoospermia

Groups Parameters

PA-LC + CoQ10 (n = 63)

PA-LC (n = 55)

PA-CoQ10 (n = 48)

OR-LC + CoQ10 (n = 66)

P-value

Patient (Male) Age (Year)

31 (22, 46)

30 (23, 47)

30 (21, 46)

30 (22, 46)

0.116†

Spouse (female) Age (Year)

30 (21, 37)

29 (23, 40)

29 (21, 40)

29 (21, 39)

0.203†

Semen parameters

 Abstinence time (Day)

3 (2, 5)

3 (2, 7)

3 (2, 7)

3 (2, 7)

0.129†

 Semen volume (ml)

4.2 ± 0.9

4.0 ± 0.8

3.8 ± 0.8

3.7 ± 0.8

0.003†

 pH

7.40 ± 0.2

7.4 ± 0.2

7.4 ± 0.2

7.4 ± 0.2

0.563†

 Liquefaction time (Min)

15 (10,20)

15 (10,15)

15 (10,20)

15 (10,20)

0.209†

 Sperm concentration (106/ml)

46.6 ± 10.7

45.7 ± 11.3

47.1 ± 11.2

47.0 ± 12.0

0.912†

 Total sperm number (106)

193.7 ± 56.5

182.3 ± 59.8

179.1 ± 58.8

171.4 ± 52.2

0.166†

 Progressive spermmotility, %

21.4 ± 6.4

20.8 ± 4.3

21.5 ± 3.0

21.4 ± 5.2

0.572†

 Total sperm motility, %

37.9 ± 6.5

37.4 ± 4.6

36.0 ± 3.3

37.5 ± 5.5

0.695†

Normal sperm morphology, %

9 (6, 12)

8 (6, 12)

9 (7, 12)

8 (6, 12)

0.914†

Length of infertility (Year)

3(1, 6)

2(1, 5)

2(1, 3)

3(1, 5)

0.251†

Testosterone (nmol/l)

16.2 ± 1.2

15.6 ± 1.7

16.0 ± 1.2

15.7 ± 1.6

0.084†

Follicle stimulating hormone (mIU/ml)

3.9 ± 1.1

4.0 ± 1.7

4.0 ± 1.3

3.8 ± 1.6

0.881†

Luteinizing hormone (mIU/ml)

3.8 ± 1.0

3.6 ± 0.7

3.7 ± 0.6

3.8 ± 0.6

0.572†

Estradiol (pmol/l)

74.7 ± 23.8

67.5 ± 19.9

71.0 ± 22.3

70.8 ± 22.5

0.373†

Prolactin (mIU/l)

124.3 ± 13.6

121.7 ± 15.3

121.0 ± 19.6

123.1 ± 18.4

0.733†

Karyotype

 Normal, %

100 (63/63)

100 (55/55)

100 (48/48)

100 (66/66)

NS

Routine urine test

 WBC, %

  (+)

4.8 (3/63)

3.6 (2/55)

4.2 (2/48)

3.0 (2/66)

0.652*

  (−)

95.2 (60/63)

96.4 (53/55)

95.8 (46/48)

97.0 (64/66)

Ligation of internal spermatic vein, %

 Yes

14.3 (9/63)

12.7 (7/55)

10.4 (5/48)

7.6 (5/66)

0.943*

 No

85.7 (54/63)

87.3 (48/55)

89.6 (43/48)

92.4 (61/66)

Testicular volume

 Left (ml)

21.3 ± 4.4

18.5 ± 4.0

21.7 ± 4.4

20.0 ± 4.2

0.067†

 Right (ml)

22.2 ± 3.6

19.7 ± 4.1

22.6 ± 3.5

20.6 ± 4.0

0.082†

Prostatic enlargement, %

 Yes

11.1 (7/63)

9.1 (5/55)

12.5 (6/48)

12.1 (8/66)

0.644*

 No

88.9 (58/63)

90.9(50/55)

87.5 (42/48)

87.9 (58/66)

History of chronic prostatitis, %

 Yes

6.4 (4/63)

12.7 (7/55)

12.5 (6/48)

10.6 (7/66)

0.067*

 No

93.7 (59/63)

87.3(48/55)

87.5 (42/48)

89.4 (59/66)

History of seminal vesiculitis, %

 Yes

3.2 (2/63)

1.8 (1/55)

4.2 (2/48)

3.0 (2/66)

0.954*

 No

96.8 (61/63)

98.2 (54/55)

95.8 (46/48)

97.0 (64/66)

Hematospermia, %

 Yes

3.2 (2/63)

1.8 (1/55)

2.1 (1/48)

3.0 (2/66)

0.957*

 No

96.8 (61/63)

98.2 (54/55)

97.9 (47/48)

97.0 (64/66)

  1. Data are presented as mean ± SD or as median (minimum, maximum) or as percentages (%)
  2. Abbreviations: PA-LC Prodom-assisted L-carnitine treatment, PA-CoQ10 Prodom-assisted Coenzyme Q10 treatment, PA-LC + CoQ10 Prodom-assisted L-carnitine combined with Coenzyme Q10 treatment, OR-LC + CoQ10 oral L-carnitine combined with Coenzyme Q10 treatment, NS not-significant, SD standard deviation, ml milliliter, l liter, pH acidity index
  3. P-values were calculated using †one-way analysis of variance (one-way ANOVA), *Chi-squared
  4. The boldface represents statistical significance